INMUNE BIO INC. - COMMON STOCK

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

15 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

01 Nov 2023 15:10:41 By Nasdaq GlobeNewswire

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

30 Oct 2023 08:07:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

16 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

07 Aug 2023 15:00:18 By Nasdaq GlobeNewswire

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

01 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

12 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

11 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

10 Jul 2023 15:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

03 May 2023 15:10:51 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

24 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

19 Apr 2023 07:30:00 By Nasdaq GlobeNewswire